



FOR IMMEDIATE RELEASE: April 1, 2022

Nigel Herrold
(844) 423-9747

Boomerang Medical Receives FDA IDE Approval to Begin Early Feasibility Study of Bioelectronic Therapy for Inflammatory Bowel Disease

Milestone marks a new opportunity for patients with Crohn's disease and ulcerative colitis to receive bioelectronic medicine therapy

MOUNTAIN VIEW, Calif.— Boomerang Medical, Inc., a women-led bioelectronic medicine company pioneering neuromodulation therapies for the treatment of autoimmune diseases announced today the US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to the company to evaluate implantable bioelectronic medicine therapy for Inflammatory Bowel Disease (IBD). Boomerang Medical's multi-center Early Feasibility Study will take place at leading IBD centers in the United States.

The incidence and prevalence of IBD, which includes ulcerative colitis and Crohn's disease, has increased significantly worldwide over the past 15 years. While IBD is generally nonfatal, people with IBD are often heavy users of the health care system. IBD patients often take medications and visit doctors frequently to achieve and maintain remission, and severe cases or those not responding to medications may require hospitalizations and surgeries.

"We are pleased to launch this new study, which puts us closer towards potentially filling a large unmet need in the treatment of Inflammatory Bowel Disease," said Heather Simonsen, Chief Executive Officer of Boomerang Medical.

Patients interested in learning more about the study should contact Malea D'Amico, Senior Director of Clinical Operations, at info@boomerangmedical.com for more information.

About Boomerang Medical

Boomerang Medical is a women-led clinical-stage company headquartered on the campus of El Camino Hospital in Mountain View, Calif. and is a Company-In-Residence at Fogarty Innovation. Boomerang is developing a technology to advance the treatment of autoimmune diseases by harnessing the body's own peripheral wiring in order to manage inflammation and immune response. For more information, visit www.boomerangmedical.com

###